It’s been a rough couple of weeks for GlaxoSmithKline. On the eve of last week’s FDA hearings to decide whether its former best-selling diabetes drug Avandia should still be sold, the New York Times broke news of the company’s efforts to conceal internal

Following up on last week’s blog discussing the FDA hearing underway to determine the safety of the prescription diabetes drug, Avandia, the FDA advisory review panel concluded a two-day hearing last Wednesday by recommending 20 to 12 that Avandia remain

Last week’s article by New York Times reporter Gardiner Harris exposed Glaxo SmithKline’s (GSK) flagrant disregard for patient safety. For 11 years GSK suppressed internal studies showing that the world’s former best selling diabetes drug, Avandia, posed

On our PostScript blog today, we posted about a Harvard study published in this month’s Health Affairs that looked at generic drugs and the potential benefit they can provide in savings to cash-strapped Medicaid programs. The researchers conclude that if

At a time when state fiscal woes are forcing cuts in Medicaid, researchers at the Division of Pharmacoepidemiology at Brigham & Women’s Hospital in Boston and Harvard Medical School have identified a policy with at least $100 million in potential savi

Community Catalyst recently worked with our partner, Georgetown University’s Center for Children and Families, to create a document answering prevalent questions about how the new mandate for insurance coverage will affect families. Here’s an excerpt from

Monday's story by New York Times reporter Gardiner Harris revealed that Glaxo SmithKline (GSK) had withheld studies showing serious risks associated with the world’s former best selling diabetes drug for 11 years. GSK withheld results from a 1999 study th

A week or so ago we blogged about comments Prescription Access Litigation and others made to the FDA in support of proposed rules on presenting risk information in broadcast drug ads. Numerous other consumer and public health groups have commented, and ov

It’s no secret that the passage of the Affordable Care Act means lots of new opportunities for health care coverage and access – and that most Americans are confused about what the law actually means for them.  Here at Community Catalyst, we have seen hea